Clinical Trial Update: Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients [Phase 2]

View source ↗

Summary

This is an extension study of subjects from Pfizer's A3921030 evaluating prevention of acute rejection in kidney transplant patients; the Phase 2 trial has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• A3921030

Snippet

Sponsor: Pfizer | Conditions: Kidney Transplantation | Phase 2 | Status: COMPLETED | Results posted: 2018-02-23